CORRECTION article

Front. Immunol., 14 April 2023

Sec. Cancer Immunity and Immunotherapy

Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1194064

Corrigendum: Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients

  • CX

    Chao Xia 1,2

  • WH

    Wei Huang 1

  • YC

    Yun-Liang Chen 3

  • HF

    Hai-Bin Fu 2

  • MT

    Ming Tang 2

  • TZ

    Tao-Lan Zhang 2

  • JL

    Jing Li 4

  • GL

    Guo-Hua Lv 4

  • YY

    Yi-Guo Yan 2

  • ZO

    Zhi-Hua Ouyang 2

  • NY

    Nvzhao Yao 2

  • CW

    Cheng Wang 2*

  • MZ

    Ming-Xiang Zou 2*

  • 1. The First Affiliated Hospital, Health Management Center, Hengyang Medical School, University of South China, Hengyang, China

  • 2. Department of Spine Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China

  • 3. Shenzhen Audaque Data Technology Co., Ltd., Shenzhen, China

  • 4. Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, China

In the published article, there was an error in the author list, and Prof. Ming-Xiang Zou was erroneously denoted as the only corresponding author of this article. Prof. Cheng Wang should be denoted as the co-corresponding author for this paper. In addition, Prof. Cheng Wang and Prof. Ming-Xiang Zou should not have been marked with the † symbol. The corrected author list appears below.

Chao Xia1,2†, Wei Huang1†, Yun-Liang Chen3, Hai-Bin Fu2, Ming Tang2, Tao-Lan Zhang2, Jing Li 4, Guo-Hua Lv4, Yi-Guo Yan2, Zhi-Hua Ouyang2, Nvzhao Yao2, Cheng Wang2* and Ming-Xiang Zou2*

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

spinal chordoma, immune checkpoint molecules, quantitative immunofluorescence, HHLA2, PD-L1, tumor infiltrating lymphocytes

Citation

Xia C, Huang W, Chen Y-L, Fu H-B, Tang M, Zhang T-L, Li J, Lv G-H, Yan Y-G, Ouyang Z-H, Yao N, Wang C and Zou M-X (2023) Corrigendum: Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients. Front. Immunol. 14:1194064. doi: 10.3389/fimmu.2023.1194064

Received

26 March 2023

Accepted

27 March 2023

Published

14 April 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

14 - 2023

Updates

Copyright

*Correspondence: Cheng Wang, ; Ming-Xiang Zou,

†These authors have contributed equally to this work

This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics